Details of the Drug | DrugMAP

General Information of Drug (ID: DMIDVZ3)

Drug Name

MK-8457

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Phase 2	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C24H25F3N4O3S
Canonical SMILES: CC1=CC(=CC(=C1)NC2=NC=CC(=N2)C(F)(F)F)C3=CN=C(S3)C4(CCC(C(C4)(C)C)C(=O)O)O
InChI: 1S/C24H25F3N4O3S/c1-13-8-14(10-15(9-13)30-21-28-7-5-18(31-21)24(25,26)27)17-11-29-20(35-17)23(34)6-4-16(19(32)33)22(2,3)12-23/h5,7-11,16,34H,4,6,12H2,1-3H3,(H,32,33)(H,28,30,31)/t16-,23-/m1/s1
InChIKey: LDDBKIFZPGDEND-WAIKUNEKSA-N

Cross-matching ID

PubChem CID: 53251506
TTD ID: D08PXL

References

1	ClinicalTrials.gov (NCT01569152) Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (MK-8457-008). U.S. National Institutes of Health.